CELLDEX THERAPEUTICS SHARES UP 21% PREMARKET AFTER CO'S SKIN CONDITION DRUG BARZOLVOLIMAB MEETS PRIMARY AND ALL KEY SECONDARY ENDPOINTS

Reuters · 1d ago

Please log in to view news